ABSTRACT
Background Antimicrobial Resistance (AMR), a major global public health threat causing 1.2 million deaths, calls for immediate action. Antimicrobial stewardship (AMS) promotes judicious antibiotic use, but the COVID-19 pandemic increased AMR by 15%. Our study evaluated AMS implementation and inappropriate antibiotic prescribing before-the-pandemic (PD) and during-the-pandemic (DP).
Methods This retrospective study examined medical records of adult patients (age 25 and above) admitted to an NHS Foundation Trust in England for respiratory tract infections (RTIs) or pneumonia in 2019 and 2020. Our objective was to evaluate antibiotic prescribing practices BP and DP in 2019 and 2020. Primary outcomes included evaluating the prevalence of inappropriate antibiotic prescribing and assessing the implementation of AMS using Public Health England’s ‘Start Smart, Then Focus’ (SSTF) toolkit. Reliable data extraction was ensured by two independent reviewers using a validated data extraction tool.
Results A total of 640 patient records (320 from 2019 and 320 from 2020) were analysed. The mean age of enrolled adults was 74.3 years in 2019 and 76.2 years in 2020. COVID pneumonia showed a significantly higher odds ratio (OR) of 20.24 (95% CI 5.82 to 128.19, p-value<0.001). Inappropriate antibiotic prescribing, as per local guidelines, increased from 36% in 2019 to 64% in 2020 for the second course of antibiotics DP. Differences were observed in AMS interventions, with an OR of 3.36 (95% CI 1.30-9.25, p=0.015) for ‘Continue Antibiotics’ and an OR of 2.77 (95% CI 1.37-5.70, p=0.005) for ‘De-escalation’.
Conclusion The COVID-19 pandemic significantly impacted antibiotic prescribing, increasing inappropriate use and posing risks of antimicrobial resistance. Factors influencing prescribing practices must be considered, and proactive measures, including updating the SSTF toolkit and developing an AMS roadmap, are needed to address the challenges of AMR in the context of evolving infectious diseases.
WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ AMR is a major global health threat, called a silent pandemic, with the potential for 10 million annual deaths by 2050, equivalent to one death every three seconds.
⇒ Antimicrobial stewardship (AMS), promoting judicious antibiotic use, plays a pivotal role in combating AMR.
⇒ The COVID-19 pandemic led to a 15% rise in AMR and hospital-associated deaths during 2020.
WHAT THIS STUDY ADDS
⇒ Evaluated the implementation of AMS before and during the COVID-19 pandemic in 2019 and 2020 across four seasonal time points.
⇒ Estimated the prevalence of inappropriate antibiotic prescribing in 2019 and 2020.
⇒ Identified factors influencing antibiotic prescribing upon admission and during the hospital stay.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY
⇒ Our study offered a comprehensive analysis of AMS implementation and identified the key factors that influence antibiotic prescribing and AMS application BP and DP. This critical understanding will be instrumental in shaping a strategic plan intended to improve antibiotic prescribing practices in acute care settings, thereby directing necessary updates and revisions in current policies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.isrctn.com/ISRCTN14825813
Funding Statement
This research study has no fund
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
East Midlands Leicester South Research Ethics Committee (REC) gave ethical approval for this work - REC Reference: 22/EM/0161 University of Hertfordshire Ethics Committee gave ethical approval for this work, under the reference LMS/PGR/NHS/02975.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The individual patient records cannot be shared by the investigators under the data use agreement with the NHS Trust studied in this paper.
